The Evidence Based Rheumatology Podcast
by Michael Putman
Is this your podcast?Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 9 chart positions in 9 markets.
By chart position
- 🇰🇷KR · Medicine#2230K to 100K
- 🇪🇸ES · Medicine#8910K to 30K
- 🇮🇩ID · Medicine#963K to 10K
- 🇬🇷GR · Medicine#110500 to 3K
- 🇨🇱CL · Medicine#136500 to 3K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
23K to 79K🎙 ~2x weekly·100 episodes·Last published 2mo ago - Monthly Reach
Unique listeners across all episodes (30 days)
46K to 158K🇰🇷63%🇪🇸19%🇮🇩6%+6 more - Active Followers
Loyal subscribers who consistently listen
14K to 47K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 13 epsHost
Recent guests
No guests detected in recent episodes.
Recent episodes
E137: Obexelimab in IgG4-RD (INDIGO)
Jun 29, 2026
15m 36s
E136: Secukinumab in PMR (REPLENISH)
Jun 15, 2026
13m 39s
E135: IL17 and a GLP1?
Apr 30, 2026
11m 03s
E134: Brepocitinib in Dermatomyositis (VALOR)
Apr 17, 2026
14m 58s
E133: Obinutuzumab for SLE (ALLEGORY)
Mar 19, 2026
15m 21s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 6/29/26 | B cell drugsIgG4-RD+3 | — | ObexelimabNEJM+1 | — | ObexelimabIgG4-RD+4 | boardsbank.com | 15m 36s | ||
| 6/15/26 | rheumatologyclinical trials+4 | — | secukinumabNEJM | — | secukinumabPMR+4 | boardsbank.com | 13m 39s | ||
| 4/30/26 | IL17 inhibitorsGLP1 inhibitors+3 | — | ixekizumabtirzepatide+2 | — | IL17GLP1+5 | — | 11m 03s | ||
| 4/17/26 | dermatomyositisbrepocitinib+3 | — | brepocitinibautoimmunedevreport.substack.com+2 | — | brepocitinibdermatomyositis+3 | — | 14m 58s | ||
| 3/19/26 | rheumatologyclinical trials+3 | — | obinutuzumabNEJM+2 | — | obinutuzumabSLE+3 | — | 15m 21s | ||
| 3/5/26 | osteoporosisromosozumab+4 | — | Romosozumab vs teriparatide for osteoproosishttps://pubmed.ncbi.nlm.nih.gov/28755782/ | — | osteoporosisromosozumab+6 | — | 13m 54s | ||
| 1/21/26 | rheumatoid arthritisvagal nerve stimulation+3 | — | NatureRESET-RA | — | RESET-RArheumatoid arthritis+3 | — | 14m 48s | ||
| 12/22/25 | rheumatologyclinical trials+4 | — | telitaciceptFDA+3 | — | telitaciceptSLE+4 | — | 13m 06s | ||
| 12/4/25 | laboratory monitoringrheumatoid arthritis+3 | — | ACR Convergence 2025E129: Long Term Routine Laboratory Monitoring in RA+1 | — | rheumatoid arthritislaboratory monitoring+3 | — | 15m 17s | ||
| 11/12/25 | autoimmune diseasespulmonary fibrosis+3 | — | nerandomilastNEJM | autoimmune ILD | nerandomilastautoimmune ILD+3 | — | 19m 03s | ||
| 9/22/25 | safetyTNFs+3 | — | TNFsCHF+3 | — | TNFsCHF+4 | — | 21m 46s | ||
| 9/8/25 | rheumatologyJAK inhibitors+4 | — | ScienceDirectORAL-SURVEILLANCE+1 | — | rheumatoid arthritisJAKs+5 | — | 14m 34s | ||
| 6/29/25 | adrenal insufficiencyprednisone+3 | — | prednisoloneJAMA Open | — | adrenal insufficiencyprednisone+3 | — | 17m 52s |
Showing 13 of 13
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Chart history for The Evidence Based Rheumatology Podcast
Peaked at #22 in South Korea, currently #22 in South Korea.
| Market | Genre | Peak | Current | Trend |
|---|---|---|---|---|
| South Korea | — | #22 | #22 | — |
| Spain | — | #89 | #89 | — |
| ID | — | #96 | #96 | — |
| GR | — | #110 | #110 | — |
| CL | — | #136 | #136 | — |
| IS | — | #138 | #138 | — |
| South Korea | — | #157 | #157 | — |
| MY | — | #163 | #163 | — |
| TH | — | #189 | #189 | — |
| Norway | — | #191 | #191 | — |
Chart Positions
10 placements across 9 markets.
Chart Positions
10 placements across 9 markets.